PTGX

Protagonist Therapeutics
PTGX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$3.49B
EV
$2.81B
Shares Outstanding
68.63M
Beta
2.25

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$68.70
P/E 2025E
-
P/Revenue 2025E
42.65x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Protagonist Therapeutics, Inc.

gainify
PTGX

Protagonist Therapeutics, Inc.

PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 c...

Sector

Healthcare

Industry

Biotechnology

CEO

Patel, Dinesh

Employees

124

IPO Date

2016-08-11

Headquarters

7707 Gateway Boulevard, Suite 140, Newark, California, 94560-1160, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.